This book provides a comprehensive and up-to-date review of all aspects of childhood Acute Lymphoblastic Leukemia, from basic biology to supportive care. It offers new insights into the genetic pre-disposition to the condition and discusses how response to early therapy and its basic biology are utilized to develop new prognostic stratification systems and target therapy. Readers will learn about current treatment and outcomes, such as immunotherapy and targeted therapy approaches. Supportive care and management of the condition in resource poor countries are also discussed in detail. This is an indispensable guide for research and laboratory scientists, pediatric hematologists as well as specialist nurses involved in the care of childhood leukemia.
This book discusses key aspects of childhood acute lymphoblastic leukemia (ALL), presenting the latest research on the biology and treatment of the disease and related issues. The cure rate for ALL has improved dramatically due to advances such as supportive care, treatment stratification based on relapse risk, and the optimization of treatment regimens. Gathering contributions by eminent scholars Pediatric Acute Lymphoblastic Leukemia is a valuable resource for pediatric hematologists as well as for medical students, interns, residents and fellows. It not only offers comprehensive insights, but also provides a springboard for future research.
New insights into the molecular biology of childhood leukemias have stimulated numerous advances in diagnostic methods, strategies for risk assessment and the development of novel therapy for genetic subtypes of the diseases. Fully revised and updated, this new edition of Childhood Leukemias provides the most comprehensive, clinically-oriented and authoritative reference dedicated to these diseases. Beginning with an overview of history, cell biology, and pathology, subsequent chapters review approaches in the evaluation and management of specific leukemias, new therapeutic development and the unique pharmacodynamics and pharmacogenetics of individual patients. New chapters include epigenetics of leukemias, leukemias in patients with Down syndrome and leukemia in adolescents and young adults. The final section covers the complications associated with the disease or its treatment and supportive care during and after treatment. Authored by leading experts, this is a 'must-have' for any physician or investigator who deals with leukemias in childhood.
This first open access European CAR-T Handbook, co-promoted by the European Society for Blood and Marrow Transplantation (EBMT) and the European Hematology Association (EHA), covers several aspects of CAR-T cell treatments, including the underlying biology, indications, management of side-effects, access and manufacturing issues. This book, written by leading experts in the field to enhance readers’ knowledge and practice skills, provides an unparalleled overview of the CAR-T cell technology and its application in clinical care, to enhance readers’ knowledge and practice skills.
Approximately 4,500 children and teens are diagnosed with leukemia in the United States and Canada each year. The illness and its treatment can have a devastating effect on family, friends, classmates, and the larger community. This newly updated edition of Childhood Leukemia contains the information and support parents need during this difficult time, including:•New treatments such as immunotherapy, tailoring drugs dosages to children's genetic profiles, and ways to deal with side effects.•Advice on how to cope with procedures, hospitalization, school, family, and financial issues.•Tips for forming a partnership with the medical team.•Poignant and practical stories from family members.•Updated resources for medical information, emotional support, and financial assistance.Parents who read this book will find understandable medical information and emotional support.
Childhood cancer, particularly leukemia, is on the rise. Leukemia strikes one child in every 25,000, and most often does so between the ages of 3 and 7. Annually, more than 2,700 children are diagnosed with leukemia in the United States. Due to advances in biotechnology and medicine, survival rates for this once-deadly disease now stand at 80%. But the psychological effects of diagnosis, removal from school, treatment, and remission or cure, linger. Here nine long-term survivors of childhood leukemia share their vivid memories and give us insight into the physiological changes, psychosocial and educational difficulties that became a constant shadow in their lives. Author Nanci Sullivan provides recommendations for ways teachers, counselors and other professionals may better help young students with leukemia cope.
Since the late 1960s, the survival rate in children and adolescents diagnosed with cancer has steadily improved, with a corresponding decline in the cancer-specific death rate. Although the improvements in survival are encouraging, they have come at the cost of acute, chronic, and late adverse effects precipitated by the toxicities associated with the individual or combined use of different types of treatment (e.g., surgery, radiation, chemotherapy). In some cases, the impairments resulting from cancer and its treatment are severe enough to qualify a child for U.S. Social Security Administration disability benefits. At the request of Social Security Administration, Childhood Cancer and Functional Impacts Across the Care Continuum provides current information and findings and conclusions regarding the diagnosis, treatment, and prognosis of selected childhood cancers, including different types of malignant solid tumors, and the effect of those cancers on childrenâ (TM)s health and functional capacity, including the relative levels of functional limitation typically associated with the cancers and their treatment. This report also provides a summary of selected treatments currently being studied in clinical trials and identifies any limitations on the availability of these treatments, such as whether treatments are available only in certain geographic areas.
Every day, 1500 Americans die of cancer, and yet for most of us this deadly disease remains mysterious. Why is it so common? Why are there so many different causes? Why does treatment so often fail? What, ultimately, is cancer? In this fascinating new book, a leading cancer researcher offers general readers clear and convincing answers to these and many other questions. Mel Greaves places cancer in its evolutionary context, arguing that we can best answer the big questions about cancer by looking through a Darwinian lens. Drawing on both ancient and more modern evolutionary legacies, he shows how human development has changed the rules of evolutionary games, trapping us in a nature-nurture mismatch. Compelling examples, from the King of Naples intestinal tumor in the 15th century, through the epidemic of scrotal skin cancer in 18th-century chimney sweeps, to the current surge of cases of prostate cancer illustrate his thesis. He also shows why the old paradigms of infectious diseases or genetic disorders have proved fruitless when trying to explain this complex and elusive disease. And finally, he looks at the implications for research, prevention, and treatment of cancer that an evolutionary perspective provides. Drawing on the most recent research, this is the first book to put cancer in its evolutionary framework. At a time when Darwinian perspectives on everything from language acquisition to economics are providing new breakthroughs in understanding, medicine seems to have much to gain from the insights provided by evolutionary biology. Written in an exceptionally lucid and entertaining style, this book will be of broad interest to all those who wish to know more about this dread disease.
